Castle Biosciences, Inc. (CSTL): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage rapide de l'oncologie de précision, Castle Biosciences, Inc. (CSTL) émerge comme une force pionnière, transformant le diagnostic du cancer par le biais de technologies de test moléculaire de pointe. En tirant parti des informations génomiques avancées et des plateformes de tests génétiques de décision innovantes, la société redéfinit la façon dont les professionnels de la santé prédisent, stratifient et personnalisent les stratégies de traitement du cancer. Leur modèle commercial unique comble le fossé critique entre la recherche génétique complexe et les solutions cliniques exploitables, offrant une clarté pronostique sans précédent pour les patients et les médecins.

Castle Biosciences, Inc. (CSTL) - Modèle commercial: partenariats clés

Collaborations avec les prestataires de soins de santé et les centres d'oncologie

Castle Biosciences maintient des partenariats avec plusieurs centres d'oncologie et prestataires de soins de santé pour étendre les capacités de test de diagnostic:

Type de partenaire	Nombre de partenariats	Domaine de mise au point
Centres d'oncologie	47	Mélanome et diagnostics de cancer dermatologique
Hôpitaux communautaires	112	Implémentation des tests de diagnostic

Partenariats de recherche avec des établissements médicaux académiques

Castle Biosciences collabore avec les établissements de recherche universitaires pour la recherche diagnostique avancée:

• Memorial Sloan Kettering Cancer Center
• Université de Californie, San Francisco
• MD Anderson Cancer Center
• Centre médical de l'Université de Stanford

Alliances stratégiques avec des entreprises de technologie de diagnostic

Partenaire technologique	Focus de partenariat	Année établie
Illumina	Technologies de séquençage génomique	2021
Thermo Fisher Scientific	Plates-formes de diagnostic moléculaire	2020

Partenariats pharmaceutiques pour la validation clinique

Partenariats pharmaceutiques actuels pour la validation et la recherche cliniques:

• Bristol Myers Squibb
• Miserrer & Co.
• Astrazeneca

Partenaire pharmaceutique	Investissement en recherche	Domaine de mise au point
Bristol Myers Squibb	3,2 millions de dollars	Validation diagnostique du mélanome
Miserrer & Co.	2,7 millions de dollars	Marqueurs de diagnostic d'immunothérapie

Castle Biosciences, Inc. (CSTL) - Modèle d'entreprise: Activités clés

Développement de tests de diagnostic moléculaire pour le cancer

Castle Biosciences se concentre sur le développement de tests de diagnostic moléculaire spécialisés pour divers types de cancer. Au quatrième trimestre 2023, la société a développé:

• Test de la décision du mélanome de décision
• Test de décisiondx-SCC pour le carcinome épidermoïde
• Test de décisiondx-um pour le mélanome uvéal

Type de test	Pénétration du marché	Volume de test annuel
Décédés-mélanome	65% de part de marché en oncologie	Environ 12 500 tests par an
DecisionDX-SCC	Pénétration du marché de la dermatologie de 42%	Environ 7 800 tests par an

Mener des études de recherche et de validation cliniques

Recherchez des mesures d'investissement pour 2023:

• Dépenses de R&D: 26,3 millions de dollars
• Études de validation clinique: 7 programmes de recherche en cours
• Documents de recherche publiés par des pairs: 14

Tests génomiques avancés et analyse des données

Capacités de test génomique:

Technologie	Capacité de traitement	Taux de précision
Profilage d'expression génique	5 000 échantillons / mois	Précision à 99,2%
Évaluation des risques moléculaires	3 500 échantillons / mois	98,7% de précision

Commercialiser les technologies de diagnostic de précision

Métriques de commercialisation pour 2023:

• Revenu total: 72,6 millions de dollars
• Couverture d'assurance commerciale: 85%
• Taux de remboursement de Medicare: 3 250 $ par test

Innovation continue des produits dans le diagnostic du cancer

Détails d'investissement en innovation:

Catégorie d'innovation	Investissement annuel	Développement de nouveaux produits
Technologie de diagnostic	18,5 millions de dollars	3 nouvelles plateformes de diagnostic
Analyse informatique	12,3 millions de dollars	2 développements d'algorithmes avancés

Castle Biosciences, Inc. (CSTL) - Modèle commercial: Ressources clés

Technologie de test génétique de décision de décision propriétaire

Castle Biosciences possède 7 tests de diagnostic approuvés par la FDA et au CE. Les principales plateformes de tests génétiques de l'entreprise comprennent:

Nom de test	Focus diagnostique	Statut de brevet
Décédés-mélanome	Pronostic du mélanome	Breveté
DecisionDX-UM	Évaluation des risques de mélanome uvéaire	Breveté

Équipe de recherche spécialisée en biologie moléculaire

Depuis le quatrième trimestre 2023, Castle Biosciences a employé 128 professionnels de la recherche et du développement.

• Scientifiques de niveau doctoral: 42
• Chercheurs en génétique: 36
• Spécialistes du développement clinique: 50

Infrastructure de séquençage génétique avancée

Investissement total d'infrastructure de recherche et développement: 24,3 millions de dollars en 2023.

Catégorie d'équipement	Montant d'investissement
Plates-formes de séquençage de nouvelle génération	9,7 millions de dollars
Instruments d'analyse moléculaire	6,2 millions de dollars

Portefeuille de propriété intellectuelle

Actifs totaux de propriété intellectuelle:

• Brevets actifs: 18
• Demandes de brevet en instance: 12
• Valeur du portefeuille IP total: 37,5 millions de dollars

Bases de données de données et de recherche cliniques

Métriques complètes de la base de données cliniques:

Caractéristique de la base de données	Mesure quantitative
Dossiers totaux des patients	87,500
Points de données génomiques	3,2 millions
Croissance annuelle de la base de données	22%

Castle Biosciences, Inc. (CSTL) - Modèle d'entreprise: propositions de valeur

Informations pronostiques personnalisées pour les patients atteints de mélanome

Castle Biosciences propose le test de mélanome décisionnel, qui fournit une évaluation personnalisée des risques génétiques avec un Taux de précision de 99%. Le test analyse 31 gènes pour stratifier le risque de patient du mélanome.

Test de la métrique	Valeur
Marqueurs génétiques analysés	31 gènes
Précision de test	99%
Pénétration du marché	Plus de 75 000 patients testés

Stratification précise du risque pour le traitement du cancer

Les tests de diagnostic moléculaire de l'entreprise fournissent une classification détaillée des risques pour divers types de cancer.

• Précision de la classification des risques de mélanome: 95,1%
• Précision pronostique pour les métastases: 92,3%
• Taux de remboursement de Medicare: 1 250 $ par test

Amélioration du soutien à la prise de décision clinique

Castle Biosciences génère des informations diagnostiques moléculaires qui aident les oncologues à prendre des décisions de traitement plus éclairées.

Métrique d'aide à la décision clinique	Performance
Précision de recommandation de traitement	87.6%
Taux d'adoption des médecins	62%

Solutions de tests génétiques non invasifs

La société développe des méthodologies de test mini-invasives pour les diagnostics de cancer.

• Temps de collecte des échantillons: moins de 5 minutes
• Test Résultat Tiraround: 7-10 jours
• Échantillon de tissu requis: minimal

Capacités de prédiction des résultats des patients améliorés

Castle Biosciences fournit une modélisation prédictive avancée pour le pronostic des patients et la réponse au traitement.

Métrique de prédiction des résultats	Performance
Précision de prédiction de survie à 10 ans	93.4%
Évaluation des risques de récidive	89.7%

Castle Biosciences, Inc. (CSTL) - Modèle d'entreprise: relations clients

Consultation directe avec les professionnels de la santé

Depuis le quatrième trimestre 2023, Castle Biosciences entretient des canaux de consultation directs avec 2 847 professionnels de la santé en oncologie et en dermatologie à travers les États-Unis.

Type de consultation	Nombre de professionnels	Fréquence d'interaction moyenne
Spécialistes en oncologie	1,623	4.2 Interactions / mois
Spécialistes en dermatologie	1,224	3.8 Interactions / mois

Soutien et éducation cliniques en cours

Castle Biosciences fournit un soutien clinique complet via plusieurs canaux.

• Sessions de formation du webinaire: 42 séances organisées en 2023
• Ressources d'éducation clinique: 87 Matériel éducatif unique
• Présentations annuelles de la conférence médicale: 12 événements

Communication personnalisée du patient

Les mesures de communication des patients pour 2023 démontrent des stratégies d'engagement ciblées.

Canal de communication	Interactions totales	Taux de satisfaction des patients
Portail des patients numériques	53 672 interactions	94.3%
Communications par e-mail personnalisées	37 845 communications	92.1%

Plateforme numérique pour l'interprétation des résultats des tests

La plate-forme numérique de Castle Biosciences a traité 64 329 résultats de test en 2023 avec une précision de 97,6%.

Mises à jour technologiques continues et améliorations

Investissement technologique pour l'amélioration de la relation client en 2023: 4,2 millions de dollars.

• Mises à niveau de la plate-forme logicielle: 3 versions majeures
• Améliorations du modèle d'apprentissage automatique: 7 itérations
• Améliorations de la cybersécurité: surveillance continue

Castle Biosciences, Inc. (CSTL) - Modèle d'entreprise: canaux

Ventes directes aux pratiques en oncologie

Castle Biosciences maintient une force de vente directe dédiée ciblant les pratiques en oncologie. Au quatrième trimestre 2023, la société a signalé 72 représentants des ventes directes spécialisées dans la dermatopathologie et le diagnostic de mélanome.

Canal de vente	Nombre de représentants	Couverture géographique
Ventes directes en oncologie	72	États-Unis

Plateformes de commande de diagnostic en ligne

La société propose Systèmes de commande de test de diagnostic basé sur le Web intégré aux plates-formes de dossiers de santé électronique (DSE).

• Plateforme numérique lancée en 2022
• Prend en charge la commande de test en temps réel pour les prestataires de soins de santé
• Interface sécurisée compatible HIPAA

Présentations de la conférence médicale

Castle Biosciences participe à 18-22 conférences majeures en oncologie et pathologie chaque année, présentant des technologies de recherche et de diagnostic.

Type de conférence	Participation annuelle	Public cible
Conférences en oncologie	12-15	Oncologistes
Conférences de pathologie	6-7	Pathologistes

Marketing numérique et télémédecine

Les dépenses de marketing numérique en 2023 étaient d'environ 2,3 millions de dollars, axée sur l'engagement professionnel ciblé des soins de santé.

Réseaux de référence professionnels de la santé

Castle Biosciences a établi des réseaux de référence avec environ 1 200 pratiques de dermatologie et d'oncologie à travers les États-Unis.

Spécialité	Nombre de pratiques en réseau
Dermatologie	850
Oncologie	350

Castle Biosciences, Inc. (CSTL) - Modèle d'entreprise: segments de clientèle

Oncologues et dermatologues

En 2023, Castle Biosciences cible environ 15 000 oncologues et 25 000 dermatologues aux États-Unis.

Spécialité	Nombre de professionnels	Pénétration du marché
Oncologistes	15,000	42%
Dermatologues	25,000	35%

Patients atteints de cancer et survivants

Castle Biosciences se concentre sur des segments spécifiques des patients atteints de cancer:

• Patients de mélanome: 106 110 nouveaux cas en 2023
• Patients de mélanome uvéal: environ 2 000 nouveaux cas par an
• Survivants du mélanome cutané: estimé 1,4 million aux États-Unis

Systèmes hospitaliers et centres de cancer

Type de client	Nombre d'institutions	Taux d'adoption
Centres de cancer complets	51	78%
Centres de cancer de la communauté	1,500	45%

Fournisseurs d'assurance de santé

Castle Biosciences a des accords de couverture avec:

• Medicare: couverture nationale complète
• Assureurs privés: 15 principaux fournisseurs d'assurance nationaux
• Taux de remboursement: moyenne de 3 200 $ par test de décision de décision.

Organisations de recherche clinique

Catégorie de recherche	Nombre de collaborations actives	Budget de recherche annuel
Organisations de recherche sur le mélanome	22	6,3 millions de dollars
Essais cliniques en oncologie	37	4,7 millions de dollars

Castle Biosciences, Inc. (CSTL) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2022, Castle Biosciences a déclaré des dépenses de R&D de 26,3 millions de dollars, ce qui représente une augmentation de 32% par rapport à 19,9 millions de dollars en 2021.

Exercice fiscal	Dépenses de R&D	Croissance d'une année à l'autre
2021	19,9 millions de dollars	-
2022	26,3 millions de dollars	32%

Frais de validation clinique

Les coûts de validation clinique pour Castle Biosciences comprennent:

• Frais d'essai cliniques directs
• Frais de recrutement des patients
• Tests de laboratoire

Dépenses de vente et de marketing

Les frais de vente et de marketing pour 2022 ont totalisé 20,1 millions de dollars, contre 15,7 millions de dollars en 2021.

Exercice fiscal	Ventes & Frais de marketing	Pourcentage de revenus
2021	15,7 millions de dollars	38%
2022	20,1 millions de dollars	42%

Maintenance des infrastructures technologiques

Les coûts de maintenance des infrastructures technologiques étaient d'environ 4,5 millions de dollars en 2022, notamment:

• Services de cloud computing
• Systèmes de cybersécurité
• Licence de logiciel
• Mises à niveau matériel

Coûts de conformité réglementaire

Les frais de conformité réglementaire pour 2022 ont été estimés à 3,2 millions de dollars, couvrant:

• Processus de soumission de la FDA
• Surveillance réglementaire continue
• Documentation de conformité

Total des dépenses d'exploitation pour 2022: 54,1 millions de dollars

Castle Biosciences, Inc. (CSTL) - Modèle d'entreprise: Strots de revenus

Ventes de tests de diagnostic

Pour l'exercice 2022, Castle Biosciences a déclaré un chiffre d'affaires total de 75,3 millions de dollars, avec une partie importante dérivée des ventes de tests de diagnostic.

Produit de test de diagnostic	Revenus annuels (2022)
Décédés-mélanome	49,2 millions de dollars
DecisionDX-SCC	12,5 millions de dollars
DecisionDX-UM	8,6 millions de dollars

Services de test de laboratoire

Castle Biosciences exploite un laboratoire certifié CLIA à Irving, au Texas, générant des revenus grâce à des services de tests génétiques spécialisés.

• Coût moyen par test: 3 500 $ à 4 500 $
• Nombre de tests effectués en 2022: environ 21 500

Licence des technologies de tests génétiques

L'entreprise génère des revenus supplémentaires grâce à des accords de licence de technologie stratégique.

Partenaire de licence	Revenus de licence estimées (2022)
Institutions universitaires	2,3 millions de dollars
Organisations de recherche pharmaceutique	1,7 million de dollars

Remboursement des assureurs de santé

Les remboursements d'assurance constituent une source de revenus critique pour Castle Biosciences.

• Taux de remboursement de l'assurance-maladie: Environ 3 200 $ par test
• Couverture principale des assureurs privés: 85% des tests remboursés
• Pourcentage de remboursement moyen: 92%

Accords de collaboration de recherche

Les partenariats de recherche fournissent des revenus supplémentaires à l'entreprise.

Type de collaboration	Revenus de collaboration annuels
Subventions de recherche universitaire	1,5 million de dollars
Partenariats de recherche pharmaceutique	2,8 millions de dollars

Castle Biosciences, Inc. (CSTL) - Canvas Business Model: Value Propositions

You're looking at the core value Castle Biosciences, Inc. (CSTL) delivers across its diagnostic portfolio as of late 2025. This isn't just about running tests; it's about providing actionable, data-driven clarity where clinical uncertainty is high. The numbers show real traction in adoption and clinical utility.

Providing personalized, risk-aligned management decisions for cutaneous melanoma (DecisionDx-Melanoma)

DecisionDx-Melanoma is the cornerstone, helping clinicians move past traditional staging. The test has achieved significant adoption, surpassing 200,000 total test orders by May 2025. In the third quarter of 2025 alone, the volume hit a milestone, exceeding 10,000 test reports for the first time in a single quarter. For the first nine months of 2025, reports totaled 29,061. The value is in the risk stratification, which has been associated with improved survival; real-world data suggests patients receiving the test saw a 29% lower 3-year melanoma-specific mortality compared to those who did not.

Here's a look at the prognostic power this test offers across different melanoma types:

Risk Group (Nodular Melanoma)	5-Year Melanoma-Specific Survival (MSS)
Class 1A (Lowest Risk)	98.5%
Class 2B (Highest Risk)	82.3%

This level of precision helps define patient pathways clearly. Furthermore, overall real-world evidence, like the NCI SEER study, points to a 32% reduction in melanoma mortality in patients utilizing the test.

Improving prognostic accuracy and reducing unnecessary procedures, like Sentinel Lymph Node Biopsy (SLNB)

The ability to accurately identify low-risk patients directly translates into avoiding invasive procedures. For patients classified as low risk by DecisionDx-Melanoma, the rate of Sentinel Lymph Node (SLN) positivity was only 2.8%. This figure is a key metric because it is significantly better than the 5% threshold set by the NCCN guidelines for ruling out the need for an SLNB. You're seeing a direct mechanism for reducing patient morbidity by providing objective data that supports a less aggressive initial management plan.

Guiding systemic treatment selection for moderate-to-severe atopic dermatitis (AdvanceAD-Tx)

Castle Biosciences, Inc. launched AdvanceAD-Tx on November 3, 2025, targeting the $33 billion U.S. Total Addressable Market for moderate-to-severe atopic dermatitis (AD). This 487-gene expression profile test is designed to tell clinicians which patients will respond best to a JAK inhibitor versus a Th2 therapy. The initial commercial rollout started with a measured, limited-access model in November 2025, with revenue contribution expected to be immaterial in 2026 as reimbursement is established.

The validation data shows a clear benefit for the identified responder group:

• 30.4% of tested samples showed a JAK inhibitor responder profile.
• EASI-90 response by three months was 45.5% for JAKi vs. 8.3% for Th2 therapies (p=0.021).
• Flare-free rates at three months were 54.5% on JAKi vs. 16.7%.
• vIGA-AD clear rates reached 36.4% with JAKi vs. 0% for the alternative (p=0.006).

Offering risk stratification for progression in Barrett's esophagus (TissueCypher)

TissueCypher provides personalized risk stratification for patients with Barrett's esophagus (BE), predicting progression to high-grade dysplasia or esophageal cancer. This is critical given that esophageal cancer carries a five-year survival rate of just 22%. The test is gaining traction, with 10,609 reports delivered in Q3 2025, marking 75% year-on-year growth for the product. Cumulative reports surpassed 25,000 since the end of 2021. The test has achieved Advanced Diagnostic Laboratory Test status from CMS.

The core value proposition here is moving beyond standard pathology to reveal high-risk patients who might otherwise be overlooked, enabling personalized surveillance or intervention strategies.

• Nine months ended September 30, 2025, TissueCypher reports: 27,211.
• Q3 2025 total test reports for core drivers (including DecisionDx-Melanoma) increased 36% year-over-year.

Overall, the company raised its full-year 2025 revenue guidance to a range of $327 million to $335 million based on this momentum.

Castle Biosciences, Inc. (CSTL) - Canvas Business Model: Customer Relationships

You're looking at how Castle Biosciences, Inc. (CSTL) keeps its clinical customers engaged, which is key since their value proposition is built on complex molecular data guiding critical decisions. The relationship is definitely high-touch, relying heavily on education and support to ensure the test results translate into actual practice changes for melanoma management.

The depth of this relationship is grounded in evidence. Castle Biosciences, Inc. (CSTL) builds its credibility on a substantial body of work supporting DecisionDx-Melanoma. This evidence base includes over 50 peer-reviewed publications, including prospective studies and meta-analyses. Furthermore, the test was developed in collaboration with more than 100 leading U.S. institutions.

The adoption rate shows how well this educational engagement is working. By the third quarter of 2025, DecisionDx-Melanoma had been ordered more than 220,000 times since its launch. This level of use requires significant ongoing clinical support and consultation for interpreting physicians to properly integrate the molecular insights with clinicopathologic factors.

Here's a quick look at the scale of adoption for core products through the first nine months of 2025:

Metric	Nine Months Ended Sept. 30, 2025	Comparison Period (Nine Months Ended Sept. 30, 2024)
DecisionDx-Melanoma Test Reports Delivered	29,061	27,336
Total Test Reports (Core Drivers)	77,817	72,000
Q3 2025 Total Test Reports (Core Drivers)	26,841	26,010 (Q3 2024)

The company achieved a significant internal milestone in Q3 2025, with DecisionDx-Melanoma test reports surpassing 10,000 in a single quarter for the first time. This growth trajectory supports the expectation of high single-digit volume growth for DecisionDx-Melanoma for the full year 2025.

Managing the customer relationship also means handling the financial side for the patient. This involves managing patient billing and complex reimbursement processes defintely. While the company raised its full-year 2025 revenue guidance to a range of $327 million to $335 million, reflecting confidence in adoption, ongoing reimbursement initiatives for existing and new tests remain a key operational focus area for sustaining this customer base.

The clinical support structure is reinforced by:

• Clinical validation in more than 10,000 patient samples for DecisionDx-Melanoma.
• The test has been shown to be associated with improved patient survival.
• The company is pursuing multiple reimbursement pathways to drive adoption for newer tests like AdvanceAD-Tx.

Castle Biosciences, Inc. (CSTL) - Canvas Business Model: Channels

You're looking at how Castle Biosciences, Inc. (CSTL) gets its diagnostic insights from the lab bench to the ordering physician, and then disseminates the supporting science. It's a complex flow, especially when you're dealing with specialized oncology and GI tests.

The primary route to market relies on direct engagement with specialists. While the exact headcount of the commercial team isn't public, we can see the investment behind this channel. Sales and marketing expenses for the third quarter of 2025 reached $32.8 million. This spend supports the team targeting dermatologists, oncologists, and gastroenterologists, as they push core products like DecisionDx-Melanoma and the newer AdvanceAD-Tx™, which leverages the existing dermatology commercial team for its phased launch.

The physical engine of this channel is the laboratory network. Castle Biosciences operates its CLIA-certified central laboratory facilities in Phoenix, Arizona and Pittsburgh, Pennsylvania. This lab processes the tissue samples sent in from physicians across the country. The volume flowing through this channel is substantial; for the nine months ended September 30, 2025, Castle Biosciences delivered 77,817 total test reports. To give you a sense of the recent pace, the third quarter of 2025 alone saw 26,841 total test reports delivered.

Delivering those results back to the ordering physician is a critical step in the channel. This happens via secure online portals and printed reports. The output volume is tracked closely: in Q3 2025, the core tests, DecisionDx-Melanoma and TissueCypher, each surpassed 10,000 test reports for the first time in a single quarter. The DecisionDx-Melanoma test, a major driver, has now surpassed 200,000 total test orders since its launch.

Disseminating the clinical validation is a channel unto itself, building the credibility that drives the sales force. Castle Biosciences actively participates in scientific conferences and publishes in peer-reviewed journals. For instance, the company held its Q3 2025 Earnings Call on November 3, 2025, and had an upcoming presentation scheduled for the Piper Sandler 37th Annual Healthcare Conference on December 02, 2025.

Here's a quick look at the volume metrics that these channels supported through the first nine months of 2025:

Metric	Value (9 Months Ended Sept 30, 2025)	Comparison Period
Total Test Reports Delivered	77,817	vs. 72,000 in the same period of 2024
DecisionDx-Melanoma Test Reports	29,061	vs. 27,336 for the same period in 2024
DecisionDx-SCC Test Reports	13,323	vs. 12,049 for the same period in 2024
MyPath Melanoma Test Reports	3,243	vs. 3,030 for the same period in 2024
DecisionDx-UM Test Reports	1,374	vs. 1,275 for the same period in 2024

The company is clearly pushing adoption across its portfolio, even while discontinuing the IDgenetix test in May 2025.

The key channels Castle Biosciences uses to reach and inform its customers include:

• - Direct sales force targeting dermatologists, oncologists, and gastroenterologists.
• - CLIA-certified central laboratory for receiving and processing tissue samples.
• - Secure online portals and printed reports for delivering test results to physicians.
• - Scientific conferences and peer-reviewed journals for disseminating clinical data.

The overall financial goal supported by these channels is the raised full-year 2025 total revenue guidance, now projected between $327 million to $335 million.

Castle Biosciences, Inc. (CSTL) - Canvas Business Model: Customer Segments

You're looking at the core groups Castle Biosciences, Inc. (CSTL) serves with its diagnostic tests as of late 2025. These segments drive the business, which saw its full-year 2025 revenue guidance raised to between $327 million and $335 million based on strong execution through the third quarter.

The primary focus remains on specialists dealing with high-risk skin conditions. Dermatologists and Mohs surgeons are the key users for tests like DecisionDx-Melanoma and DecisionDx-SCC. The momentum here is clear; in the third quarter of 2025, DecisionDx-Melanoma alone surpassed 10,000 test reports for the first time in a single quarter, a significant adoption milestone. Management confirmed expectations for high single-digit volume growth for DecisionDx-Melanoma for the full year 2025 compared to 2024.

Next, you have gastroenterologists managing patients with Barrett's esophagus (BE). This group relies on the TissueCypher® Barrett's Esophagus test to predict the future development of high-grade dysplasia and/or esophageal cancer. This segment is part of the gastrointestinal testing franchise showing strength; TissueCypher also surpassed 10,000 test reports in the third quarter of 2025. For context, TissueCypher test reports delivered in the fourth quarter of 2024 were 6,672, showing substantial growth into 2025.

Oncologists and other specialists treating uveal melanoma and high-risk skin cancer are served by tests like DecisionDx-UM. While the volume data for uveal melanoma is less frequently highlighted in the latest summaries, the overall non-dermatologic revenue stream, which includes BE and UM, grew by 67% over the third quarter of 2024, showing rapid expansion in these areas.

A newer, emerging segment involves patients with moderate-to-severe atopic dermatitis (AD) considering systemic therapy. Castle Biosciences, Inc. launched its test, AdvanceAD-Tx™, in November 2025 to guide these treatment decisions. This test targets what the company described as a $33 billion total addressable market opportunity in the U.S. alone, though management expects its revenue contribution to be immaterial in 2026 as reimbursement pathways develop. The company is leveraging its existing dermatology commercial team for this launch.

Here's a quick look at the volume performance driving revenue from these core physician groups in Q3 2025:

Customer Focus Area	Key Test(s)	Q3 2025 Test Reports Delivered	Year-over-Year Volume Change (Core Drivers)
Cutaneous Melanoma Risk	DecisionDx-Melanoma	Over 10,000 (Milestone)	36% increase for core drivers vs Q3 2024
Barrett's Esophagus Progression	TissueCypher®	Over 10,000 (Milestone)	36% increase for core drivers vs Q3 2024
General Skin Cancer/Other	Total Test Reports	26,841	Total Q3 2025 Volume vs Q3 2024: 26,841 vs 26,010

The overall customer base is being addressed by a portfolio that generated $83.0 million in revenue for the third quarter of 2025.

You can see how the segments map to the company's recent operational metrics:

• - Dermatologists/Mohs surgeons: Drive DecisionDx-Melanoma volume, which surpassed 200,000 total orders since launch as of Q1 2025.
• - Gastroenterologists: Drive TissueCypher volume, which saw 7,432 reports in Q1 2025, a 117% year-over-year increase.
• - Oncologists/Specialists (Uveal Melanoma/High-Risk): Contribute to the non-dermatologic revenue stream that grew 67% in Q3 2025 over Q3 2024.
• - Patients with AD: Targeted by the newly launched AdvanceAD-Tx, aiming at a $33 billion U.S. market.

Finance: draft 13-week cash view by Friday.

Castle Biosciences, Inc. (CSTL) - Canvas Business Model: Cost Structure

You're looking at the core expenses driving Castle Biosciences, Inc.'s operations as of late 2025. These costs reflect the heavy lift required to commercialize specialized diagnostic tests and build out the pipeline.

High sales and marketing expenses to drive test adoption are a major component. For the third quarter of 2025, Castle Biosciences reported Sales and marketing expenses of $32.8 million, up from $29.8 million in the third quarter of 2024. This spending fuels the adoption of tests like DecisionDx-Melanoma and TissueCypher, which saw total test report volume increase by 36% over Q3 2024. The total Selling, general and administrative expense for Q3 2025 was even higher at $55,907 thousand.

The company maintains significant R&D investment for pipeline development and clinical validation. Research and development expenses for the three months ended September 30, 2025, totaled $12,960 thousand. For the first nine months of 2025, R&D spending reached $38,335 thousand. This investment supports programs like the AdvanceAD-Tx test, which targets a $33 billion addressable market in atopic dermatitis.

Cost of sales, including lab operations and personnel, is another key area. For the third quarter of 2025, Cost of sales (exclusive of amortization of acquired intangible assets) was $18,704 thousand. Over the first nine months of 2025, this cost category amounted to $52,713 thousand. The company noted that a significant portion of this expense represents fixed costs associated with testing operations, including personnel and lab services.

Finally, Amortization of acquired intangible assets creates a non-cash drag on reported net income. For the first quarter of 2025, Amortization of acquired intangible assets was reported as $28.3 million. This specific quarter was impacted by a one-time acceleration of amortization expense related to the discontinuation of the IDgenetix test, totaling approximately $20.1 million for that period.

Here's a look at the operating expense breakdown for the latest reported quarter, Q3 2025, alongside the specific figures mentioned:

Expense Category	Period	Amount (in thousands or as specified)	Source Context
Sales and Marketing Expense	Q3 2025	$32,800 thousand (or $32.8 million)	Driving test adoption
Total SG&A Expense	Q3 2025	$55,907 thousand	Total Selling, general and administrative
Research and Development	Q3 2025	$12,960 thousand	Pipeline investment
Cost of Sales (excl. Amort.)	Q3 2025	$18,704 thousand	Lab operations and personnel
Amortization of Acquired Intangible Assets	Q1 2025	$28.3 million	Impact on net income

The total operating expenses, including cost of sales, for Q3 2025 were $89.8 million, up from $80.7 million in Q3 2024.

You should review the relationship between the high Sales and Marketing spend and the growth in core test reports, which was 36% year-over-year in Q3 2025. Finance: draft 13-week cash view by Friday.

Castle Biosciences, Inc. (CSTL) - Canvas Business Model: Revenue Streams

You're looking at the engine driving Castle Biosciences, Inc.'s current financial picture, which is heavily reliant on test volume and payer coverage. The company has a clear, upward revision to its financial expectations for the year, reflecting strong execution in its core franchises. Castle Biosciences raised its full-year 2025 total revenue guidance to a range of \$327 million to \$335 million, up from the prior projection of \$310 million to \$320 million. This confidence stems from a solid third quarter, where net revenues hit \$83 million.

The revenue streams are clearly anchored by established molecular diagnostics, but diversification is picking up pace. Honestly, the growth in non-dermatologic tests is a key story here, showing the strategy is working, even if reimbursement remains a hurdle for newer offerings. Here's a quick look at how the key revenue drivers performed in Q3 2025:

Revenue Driver Component	Q3 2025 Test Reports	Year-over-Year Volume Growth
DecisionDx-Melanoma	Surpassed 10,000	Reacceleration to 12% (Q3)
TissueCypher	10,609	Reported 75% year-on-year growth (Q3)
Core Drivers (Melanoma + TissueCypher)	26,841 Total Reports	36% increase over Q3 2024
Non-Dermatologic Revenue	N/A	Increased 67% over Q3 2024

The established tests are definitely carrying the load right now. DecisionDx-Melanoma, which predicts lymph node involvement and recurrence risk, saw its growth reaccelerate to 12% in the third quarter. TissueCypher, which addresses Barrett's esophagus, delivered 10,609 test reports in that same period. When you combine these two core revenue drivers, the total test report volume grew 36% year-over-year for the quarter. This momentum is what pushed management to raise that full-year guidance by about \$16 million.

You can't talk about revenue without talking about who pays the bill. Reimbursement from commercial payers and government programs like Medicare/Medicaid is critical for realizing the value of these tests. While the company is pushing for broader adoption, they are actively managing payer dynamics. For instance, efforts to secure reconsideration requests for DecisionDx-SCC by Medicare contractors have been validated, which is a positive development. However, the DecisionDx-SCC test faced a material risk due to a Novitas Local Coverage Determination (LCD) signifying noncoverage by Medicare, which became effective on April 24, 2025. To enhance future reimbursement opportunities for the flagship melanoma test, Castle Biosciences is preparing an FDA submission for DecisionDx-Melanoma.

Diversification is a clear goal, and the numbers show it's happening, albeit from a smaller base. Revenue from non-dermatologic tests grew a substantial 67% year-over-year in Q3 2025. This segment includes the newly launched AdvanceAD-Tx, which targets a massive \$33 billion total addressable market in the U.S. alone. To be fair, the immediate revenue impact from this new test is expected to be minimal, as management projects the contribution from AdvanceAD-Tx to be immaterial in 2026 while they work through the necessary reimbursement pathways. Still, the growth in the existing non-dermatologic portfolio, like TissueCypher, is helping balance the revenue base.